1. Scrip
  2. >>Business
  3. >>Deals

AstraZeneca Nabs CinCor’s Hypertension Asset In $1.3bn Acquisition

Potential Combination With Farxiga

 
• By Ayisha Sharma

The UK major is acquiring CinCor in a deal that could be worth up to $1.8bn, in return getting hold of its Phase II hypertension candidate, baxdrostat, which offers combination potential with Farxiga.    

Heart made out of red puzzle pieces with one piece missing
CinCor's Asset Circumvents The Typical Cortisol Reduction Problem • Source: Shutterstock

AstraZeneca PLC is acquiring CinCor Pharma, Inc. for $1.3bn upfront in a bid to bolster its cardiorenal pipeline through the addition of a next-generation aldosterone synthase inhibitor (ASI) asset that could pair well with Farxiga. The company announced the deal on the opening day of the J.P. Morgan Healthcare Conference on 9 January. 

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business